GLP-1 Weight Loss Drugs and Their Impact on Value-Based Care
A group of drugs known as glucagon-like peptides 1 (GLP-1) were originally developed to better manage diabetes. But GLP-1 drugs such as Ozempic, Mounjaro and Wegovy have more recently been used to combat obesity, with some users reporting weight loss of 60 pounds or more that remains permanent so long as they continue taking the medication. A new study released by the manufacturer of Wegovy also concluded that using the drug for weight loss reduces the risk of serious cardiovascular episodes by about 20%. Manufacturers are also formulating new GLP-1s that may be even more effective in achieving dramatic and permanent weight loss.
That begs the question: Will these drugs play a role in value-based care for patients with chronic conditions such as obesity, or will the cost of GLP-1s take such a proposition off the table?
Learning Objectives:
- What are GLP-1 drugs and how do they work?
- The GLP-1 price/cost curve
- The impact of GLP-1 on the health of patients/users
- Who is being prescribed GLP-1 drugs?
- How GLP-1s have been contributing to overall healthcare costs in the U.S.
- Will GLP-1 drugs impact the volumes of bariatric surgery?
- Employer, payer and provider opinions and responses to the use of GLP-1s for weight control
- What the future holds for GLP-1 drugs and value-based cared
Speaker
Company
Event Webpage (Available for subscribers only)
Category(s): Pharmaceutical, Popular, Value Based Care
Format
Contact Speaker / Organization (Available for subscribers only)